Propanc Biopharma Inc (PPCB)

[kimq1234]

PPCB is leading the way in cancer research as a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancer. At the end of last month the Company had a major announcement regarding their lead drug, PRP, and its therapeutic potential to improve outcomes for cancer patients. Their most recent scientific study observed an extraordinary reduction of Epithelial to Mesenchymal Transition (EMT) markers from the use of PRP. What they found is that PRP reverses the EMT process which totally stops tumor progression and metastasis. Not only is the EMT process reversed, but PRP blocks the development of Cancer Stem Cells (CSCs). Keep yourself updated on PPCB as the Company moves closer and closer to cancer therapies